Phio Pharmaceuticals Corp. (PHIO) - Q2 2024 10-Q Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended June 30, 2024. Phio Pharmaceuticals Corp. is a clinical-stage biotechnology company developing immuno-oncology therapeutics using its proprietary INTASYL® small interfering RNA gene silencing technology. The Company's lead product candidate, PH-762, is currently in a Phase 1b clinical trial for cutaneous squamous cell carcinoma, melanoma, and Merkel cell carcinoma. Effective July 5, 2024, the Company completed a 1-for-9 reverse stock split.
Key Financial Metrics
| Metric (in thousands) | Q2 2024 | Q2 2023 | YTD 2024 | YTD 2023 |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Loss | $(1,846) | $(2,549) | $(4,000) | $(6,151) |
| Operating Expenses | $1,914 | $2,547 | $4,123 | $6,149 |
| Cash and Cash Equivalents (End of Period) | $4,698 | $11,307 | $4,698 | $11,307 |
| Stockholders' Equity | $3,773 | $9,904 | $3,773 | $9,904 |
| Net Cash Used in Operating Activities (YTD) | $(3,788) | $(5,479) | $(3,788) | $(5,479) |
Note: The Company has no product revenue. All figures are in thousands except per share data.
Material Changes vs. Prior Period
- Expense Reduction: Total operating expenses decreased by 25% in Q2 2024 compared to Q2 2023 ($1.9M vs. $2.5M) and by 33% on a year-to-date basis. This reduction is attributed to a cost rationalization program, including a 36% headcount reduction and the expiration of the corporate headquarters lease in March 2024.
- Collaboration Termination: In May 2024, the Company terminated its Clinical Co-Development Agreement with AgonOx, Inc. regarding the development of PH-762 treated DP TIL. The Company remains obligated to pay approximately $344,000 in accrued costs but is no longer liable for future development costs under the agreement.
- Financing Activity: Unlike the prior year, there were no equity financings during the six months ended June 30, 2024. A purchase agreement with Triton Funds LP entered in May 2024 was terminated in July 2024 with no shares sold.
- Stock Split: A 1-for-9 reverse stock split was effected on July 5, 2024, to regain compliance with Nasdaq minimum bid price requirements.
Outlook, Risks, and Management Commentary
- Liquidity and Going Concern: The Company has raised substantial doubt regarding its ability to continue as a going concern. With cash of $4.7 million as of June 30, 2024, management estimates funds will support operations into Q2 2025. Additional capital is required to continue operations.
- Subsequent Financing: In July 2024, the Company completed a financing transaction involving the exercise of existing warrants at a reduced price and the issuance of new warrants, generating approximately $2.6 million in net proceeds.
- Nasdaq Compliance: The Company received notice of non-compliance with Nasdaq minimum stockholders' equity requirements ($2.5 million threshold). While currently compliant with the minimum bid price rule following the reverse split, failure to maintain equity levels could result in delisting.
- Clinical Progress: The Phase 1b trial for PH-762 is ongoing. A safety monitoring committee recommended dose escalation in May 2024, and enrollment is expected to complete in Q2 2025.
Investor Verification Checklist
- Cash Runway: Verify the impact of the July 2024 financing ($2.6M proceeds) on the projected cash runway into Q2 2025.
- Nasdaq Status: Monitor stockholders' equity levels to ensure they remain above the $2.5 million threshold required for continued listing on the Nasdaq Capital Market.
- AgonOx Obligations: Confirm the status of the $344,000 remaining payment obligation to AgonOx and the wind-down of the associated clinical trial.
- Dilution Risk: Review the terms of the July 2024 warrant exercises and new warrant issuances, noting the significant number of shares held in abeyance (328,758 shares) due to beneficial ownership limitations.
- Cost Rationalization: Assess whether the reduced headcount and remote operations model will sustain the necessary pace of the PH-762 clinical trial.